Questions for Secondary Immune Deficiencies from Biological Agents
Please complete the form below before starting the evaluation.
Time limit: 0
Evaluation Summary
0 of 5 Questions completed
Questions:
Information
You have already completed the evaluation before. Hence you can not start it again.
Evaluation is loading…
You must sign in or sign up to start the evaluation.
You must first complete the following:
Results
Evaluation complete. Results are being recorded.
Results
0 of 5 Questions answered correctly
Time has elapsed
You have reached 0 of 0 point(s), (0)
Earned Point(s): 0 of 0, (0)
0 Essay(s) Pending (Possible Point(s): 0)
Categories
- Not categorized 0%
- 1
- 2
- 3
- 4
- 5
- Current
- Review
- Answered
- Correct
- Incorrect
-
Question 1 of 5
1. Question
- Treatment with Rituxin causes a rapid depletion in which cells
-
Question 2 of 5
2. Question
- Screening patients for antibody deficiencies before and after Rituxin therapy may allow for earlier identification of patients at risk, and help identify patients who may benefit from immunoglobulin replacement therapy
-
Question 3 of 5
3. Question
- Patients treated with TNF inhibitors may receive live viral vaccines.
-
Question 4 of 5
4. Question
- What is the most common infection associated with Eculizumab?
-
Question 5 of 5
5. Question
- In general, biologics directed at cytokines have few adverse effects and generally do not cause an increase in infectious disease susceptibility